Keyphrases
COVID-19
73%
Hepatocellular Carcinoma
70%
T Cells
56%
Immune Checkpoint Inhibitors
52%
Tumor
52%
Programmed Death-ligand 1 (PD-L1)
45%
CyTOF
42%
Dendritic Cells
41%
Mass Cytometry
41%
NY-ESO-1
34%
Cancer Immunotherapy
32%
Immune Response
32%
Macrophages
31%
CD8+ T Cells
30%
Multiple Myeloma
29%
Overall Survival
28%
In Cancer
27%
Immune Cells
26%
Innate Immune Response
25%
Inflammation
25%
Immunophenotyping
24%
Clinical Outcomes
24%
Monocytes
24%
Immuno-oncology
23%
Tumor Microenvironment
23%
Tumor Immunity
23%
B Cells
22%
Immune Parameters
22%
Nivolumab
21%
Melanoma
21%
Progression-free Survival
20%
Peripheral Immune Cells
19%
Bone Marrow
19%
Antibody Response
19%
Whole Blood
19%
Peripheral Blood Mononuclear Cells
18%
Anticancer Immune Response
18%
Clinical Trials
18%
Phase II Trial
18%
Single-cell Analysis
17%
Myeloid Cells
17%
Immune Microenvironment
17%
Ipilimumab
17%
Cancer Cells
16%
Natural Killer Cells
16%
Cancer-testis Antigen
16%
Single-cell RNA Sequencing (scRNA-seq)
16%
Immune Profiling
16%
Immune Monitoring
16%
Oncology Biomarkers
16%
Glioblastoma
16%
Cancer Vaccine
16%
Vaccination
16%
Mount Sinai
15%
Acute COVID-19
15%
PD-1 Blockade
15%
Crohn's Disease
15%
Cell Population
15%
Neoantigen
15%
Randomized Trial
15%
Non-small Cell Lung Cancer (NSCLC)
15%
Tumor Cells
14%
Interferon-α (IFN-α)
14%
Monotherapy
14%
Advanced Hepatocellular Carcinoma
14%
Lung
14%
Immunogenicity
13%
Treatment-related Adverse Events
13%
Liver
12%
CD8+
12%
Tumor Antigen
12%
Checkpoint Blockade
12%
Dengue Virus
12%
Ovarian Cancer
12%
Breast Cancer
12%
High-risk Human Papillomavirus (HR-HPV)
12%
Immune Landscape
12%
Peripheral Blood
12%
Host Response
12%
Immune System
11%
Granulocyte Colony-stimulating Factor (G-CSF)
11%
Adverse Events
11%
Solid Tumors
11%
Epitope
11%
Lung Cancer
11%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
11%
Confidence Interval
11%
Clinical Response
11%
Toll-like
11%
Regulatory T Cells
11%
Adaptive Immune Response
11%
Atezolizumab Plus Bevacizumab
11%
Immune Checkpoint Inhibitor Therapy
10%
Ulcerative Colitis
10%
Immune Checkpoint Blockade
10%
Pro-tumorigenic
10%
Inflammatory Cytokines
10%
Disease Progression
10%
Disease Severity
10%
Cancer Patients
10%
Immunology and Microbiology
T Cell
100%
Immunotherapy
68%
Immunocompetent Cell
54%
COVID-19
50%
Immune Response
47%
Myeloid
41%
Macrophage
40%
Dendritic Cell
39%
Cytotoxic T-Cell
39%
Monocyte
38%
Vaccine Efficacy
38%
Mass Cytometry
35%
Cytokine
34%
Multiple Myeloma
34%
B Cell
28%
Vaccination Policy
27%
T-Helper Cell
26%
Human Immunodeficiency Virus
25%
Overall Survival
25%
Intravenous Immunoglobulin
22%
Severe Acute Respiratory Syndrome Coronavirus 2
22%
Neoantigen
21%
Mouse
20%
RNA Sequence
20%
Progression Free Survival
20%
interferon
20%
Programmed Death-Ligand 1
18%
Tumor Necrosis Factor
18%
Epitope
18%
Cell Population
18%
Natural Killer Cell
17%
Regulatory T Cell
17%
Peripheral Blood Mononuclear Cell
17%
CD8
17%
Immunofluorescence
16%
Transplant Procedure
15%
Immune Landscape
15%
Crohn's Disease
15%
Cancer Cell
15%
Monospecific Antibody
15%
Single Cell Analysis
15%
Upregulation
14%
Ipilimumab
14%
Antibody Response
14%
Blood Plasma
13%
Squamous Cell
13%
Immune System
13%
Neck
13%
Humoral Immunity
13%
Adoptive Immunity
13%
Phenotype
12%
Gene Expression
12%
Bevacizumab
12%
Hepatitis C
12%
Cancer Immunotherapy
11%
Immune Checkpoint Blockade
11%
Mouse Model
11%
Interleukin-6
11%
Tumor Antigen
11%
Granulocyte Macrophage Colony-Stimulating Factor
11%
Dengue Virus
11%
Inflammation Response
11%
Lymphocyte
11%
Chemokine
11%
Cancer Vaccine
10%
Neutrophil
10%
CD4
10%
Tumor Cell
10%
Cancer Testis Antigen
10%
T Cell Subset
10%
Carcinoma Cell
10%
CTLA-4
9%
Viral Disease
9%
Immunology
9%
T Cell Receptor
9%
Wart Virus
9%
Atezolizumab
9%
Human Leukocyte Antigen
9%
Ulcerative Colitis
9%
Memory T Cell
9%
Innate Immune System
9%
Plasmablast
9%
Antigen Specificity
8%
Toll-Like Receptor
8%
Transcriptome
8%
Plasma Cell
8%
Immunogenicity
8%
Neutrophil Granulocyte
8%
Nivolumab
8%
Epigenetics
7%
Immune Dysregulation
7%
Human Immunodeficiency Virus 1
7%
Tumor-Associated Macrophage
7%
Lymph Node
7%
Stem Cell Transplant
7%
Programmed Death 1 Receptor
7%
Hematopoietic Stem Cell
7%
Platelet Derived Growth Factor B
7%
Tumor-Infiltrating Lymphocytes
7%
Plasmacytoid Dendritic Cell
7%
Medicine and Dentistry
Neoplasm
83%
Immunotherapy
76%
Malignant Neoplasm
75%
COVID-19
58%
Hepatocellular Carcinoma
58%
Biological Marker
56%
Immune Checkpoint Inhibitor
45%
T Cell
43%
Immune Response
40%
Disease
36%
Macrophage
30%
Clinical Trial
27%
Overall Survival
27%
Severe Acute Respiratory Syndrome Coronavirus 2
24%
Progression Free Survival
24%
Immunocompetent Cell
24%
Immunoglobulin
23%
Nodular Melanoma
23%
Dendritic Cell
22%
Cytotoxic T-Cell
21%
Monocyte
20%
Oncology
19%
Infection
19%
Adverse Event
19%
Nivolumab
19%
Human Immunodeficiency Virus
18%
Mass Cytometry
18%
Programmed Death-Ligand 1
18%
Cytokine
17%
Multiple Myeloma
16%
Tumor Microenvironment
15%
Immunohistochemistry
15%
Ipilimumab
15%
Interferon
14%
Lung Cancer
14%
Cancer Immunotherapy
13%
Non Small Cell Lung Cancer
13%
CTLA-4
13%
Gene Expression
12%
RNA Sequence
12%
Serositis
12%
Breast Cancer
12%
Cytometry
11%
Medicine
11%
Cell Population
10%
Immunophenotyping
10%
T-Cell Response
10%
Lymphocyte
10%
Epitope
9%
Cisplatin
9%
Immunofluorescence
9%
Surgery
9%
Gemcitabine
9%
Myeloid Cell
9%
Cancer Cell
9%
Solid Malignant Neoplasm
9%
Tumor Antigen
9%
Cohort Analysis
8%
B Cell
8%
Antivirus Agent
8%
Ganglioglioma
8%
Immunology
8%
Receptor
8%
T Lymphocyte Receptor
8%
Proteomics
8%
Programmed Death 1 Receptor
8%
Glioblastoma
8%
Recurrent Disease
8%
Cancer Testis Antigen
7%
Cancer Therapy
7%
Monotherapy
7%
Tumor Necrosis Factor
7%
Asthma
7%
Antibody Response
7%
Natural Killer Cell
7%
Low Drug Dose
7%
Ovarian Cancer
7%
Stem Cell Transplant
7%
Phenotype
6%
CD8 Antigen
6%
Peripheral Blood Mononuclear Cell
6%
Liver Graft
6%
Arm
6%
Melanoma Antigen
6%
Muscle Invasive Bladder Cancer
6%
Urinary System
6%
Cancer Vaccine
6%
Metastatic Carcinoma
6%
Head and Neck Squamous Cell Carcinoma
6%
Ex Vivo
6%
Tumor Infiltrating Lymphocyte
6%
Inflammatory Disorder
6%
Granulocyte Macrophage Colony Stimulating Factor
6%
Metastatic Colorectal Cancer
6%
Atherosclerosis
6%
Common Variable Immunodeficiency
6%
Clear Cell Renal Cell Carcinoma
6%
Lentivirus Vector
6%
Conservative Treatment
6%
Urothelial Cancer
6%